nodes	percent_of_prediction	percent_of_DWPC	metapath
Travoprost—PTGFR—ovarian follicle—hematologic cancer	0.155	0.844	CbGeAlD
Travoprost—PTGFR—lung—hematologic cancer	0.0109	0.0592	CbGeAlD
Travoprost—PTGFR—testis—hematologic cancer	0.0103	0.0559	CbGeAlD
Travoprost—PTGFR—lymph node—hematologic cancer	0.00744	0.0405	CbGeAlD
Travoprost—Latanoprost—SLC22A1—hematologic cancer	0.00275	1	CrCbGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL13—hematologic cancer	0.000864	0.00524	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCR7—hematologic cancer	0.000864	0.00524	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—CNR2—hematologic cancer	0.000835	0.00507	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—TRH—hematologic cancer	0.000803	0.00487	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—LPAR1—hematologic cancer	0.000778	0.00472	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CCL17—hematologic cancer	0.000758	0.00461	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CXCR5—hematologic cancer	0.000744	0.00452	CbGpPWpGaD
Travoprost—PTGFR—G alpha (q) signalling events—RASGRP1—hematologic cancer	0.000737	0.00447	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CNR2—hematologic cancer	0.000716	0.00435	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—PTGER4—hematologic cancer	0.000691	0.0042	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—hematologic cancer	0.000659	0.004	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CCR7—hematologic cancer	0.000658	0.00399	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CXCL13—hematologic cancer	0.000658	0.00399	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCL3—hematologic cancer	0.000615	0.00374	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—TRH—hematologic cancer	0.000611	0.00371	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—CXCR4—hematologic cancer	0.000611	0.00371	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—GRB2—hematologic cancer	0.000593	0.0036	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—PTGER4—hematologic cancer	0.000592	0.0036	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—LPAR1—hematologic cancer	0.000592	0.0036	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CNR2—hematologic cancer	0.000545	0.00331	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCR4—hematologic cancer	0.000523	0.00318	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—JAK1—hematologic cancer	0.000511	0.0031	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—RHOJ—hematologic cancer	0.000501	0.00304	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—ARHGEF12—hematologic cancer	0.00049	0.00298	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—ARHGEF1—hematologic cancer	0.000478	0.0029	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CCL3—hematologic cancer	0.000469	0.00285	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—PTHLH—hematologic cancer	0.000463	0.00281	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—PTGER4—hematologic cancer	0.000451	0.00274	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IFT172—hematologic cancer	0.000446	0.00271	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—ARHGEF12—hematologic cancer	0.000445	0.0027	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—ARHGEF1—hematologic cancer	0.000434	0.00264	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CXCR5—hematologic cancer	0.000421	0.00255	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PPEF1—hematologic cancer	0.000408	0.00248	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—GNA13—hematologic cancer	0.000406	0.00247	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—TIAM1—hematologic cancer	0.0004	0.00243	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CXCR4—hematologic cancer	0.000398	0.00242	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—hematologic cancer	0.000391	0.00237	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CCL17—hematologic cancer	0.000389	0.00236	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—JAK3—hematologic cancer	0.000388	0.00235	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CXCR5—hematologic cancer	0.000382	0.00232	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—CREB1—hematologic cancer	0.000378	0.0023	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CCR7—hematologic cancer	0.000372	0.00226	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CXCL13—hematologic cancer	0.000372	0.00226	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—hematologic cancer	0.000369	0.00224	CbGpPWpGaD
Travoprost—PTGFR—G alpha (q) signalling events—PIK3R1—hematologic cancer	0.000369	0.00224	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—GNA13—hematologic cancer	0.000369	0.00224	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—TIAM1—hematologic cancer	0.000363	0.0022	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—IL3RA—hematologic cancer	0.000362	0.0022	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—JAK3—hematologic cancer	0.000352	0.00214	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—hematologic cancer	0.000352	0.00214	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—RGS2—hematologic cancer	0.000349	0.00212	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—TRIO—hematologic cancer	0.000345	0.0021	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—TRH—hematologic cancer	0.000345	0.0021	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CXCL13—hematologic cancer	0.000337	0.00205	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CCR7—hematologic cancer	0.000337	0.00205	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—LPAR1—hematologic cancer	0.000335	0.00203	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3R1—hematologic cancer	0.00033	0.002	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—IL3RA—hematologic cancer	0.000329	0.002	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HDAC11—hematologic cancer	0.000323	0.00196	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—hematologic cancer	0.000321	0.00195	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—RGS2—hematologic cancer	0.000317	0.00193	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—TRIO—hematologic cancer	0.000314	0.00191	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—TRH—hematologic cancer	0.000314	0.00191	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—BCR—hematologic cancer	0.000309	0.00188	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CNR2—hematologic cancer	0.000308	0.00187	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PDE4B—hematologic cancer	0.000308	0.00187	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—LPAR1—hematologic cancer	0.000304	0.00185	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—RAC2—hematologic cancer	0.000303	0.00184	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—ADCY7—hematologic cancer	0.00029	0.00176	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HDAC10—hematologic cancer	0.000288	0.00175	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CNR2—hematologic cancer	0.00028	0.0017	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PDE4B—hematologic cancer	0.00028	0.0017	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—RAC2—hematologic cancer	0.000275	0.00167	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCL2—hematologic cancer	0.000274	0.00167	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—ARHGEF12—hematologic cancer	0.000263	0.0016	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—ADCY7—hematologic cancer	0.000263	0.0016	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PTHLH—hematologic cancer	0.000262	0.00159	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—ARHGEF1—hematologic cancer	0.000256	0.00156	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PTGER4—hematologic cancer	0.000255	0.00155	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CCL3—hematologic cancer	0.00024	0.00146	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PTHLH—hematologic cancer	0.000238	0.00144	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—hematologic cancer	0.000235	0.00143	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PTGER4—hematologic cancer	0.000231	0.00141	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—AGRN—hematologic cancer	0.00023	0.0014	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CCL17—hematologic cancer	0.00023	0.0014	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CXCR5—hematologic cancer	0.000226	0.00137	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CXCR4—hematologic cancer	0.000225	0.00137	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—hematologic cancer	0.000225	0.00137	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—LEF1—hematologic cancer	0.000222	0.00135	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—GNA13—hematologic cancer	0.000218	0.00132	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—IL3—hematologic cancer	0.000217	0.00132	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TIAM1—hematologic cancer	0.000214	0.0013	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—RASGRP1—hematologic cancer	0.00021	0.00128	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CCL2—hematologic cancer	0.000209	0.00127	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—JAK3—hematologic cancer	0.000208	0.00126	CbGpPWpGaD
Travoprost—PTGFR—G alpha (q) signalling events—PIK3CA—hematologic cancer	0.000208	0.00126	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CXCR4—hematologic cancer	0.000204	0.00124	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—hematologic cancer	0.000202	0.00123	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CXCL13—hematologic cancer	0.000199	0.00121	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CCR7—hematologic cancer	0.000199	0.00121	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—IL3—hematologic cancer	0.000197	0.0012	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—NCOR2—hematologic cancer	0.000197	0.00119	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CRKL—hematologic cancer	0.000194	0.00118	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IL3RA—hematologic cancer	0.000194	0.00118	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—RASGRP1—hematologic cancer	0.000191	0.00116	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—GRB2—hematologic cancer	0.000189	0.00115	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—RGS2—hematologic cancer	0.000187	0.00114	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—hematologic cancer	0.000186	0.00113	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TRH—hematologic cancer	0.000185	0.00113	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TRIO—hematologic cancer	0.000185	0.00113	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CMA1—hematologic cancer	0.000185	0.00113	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—AGO2—hematologic cancer	0.000181	0.0011	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SPHK1—hematologic cancer	0.000181	0.0011	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—LPAR1—hematologic cancer	0.000179	0.00109	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HDAC9—hematologic cancer	0.000179	0.00109	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—H3F3B—hematologic cancer	0.000178	0.00108	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—hematologic cancer	0.000172	0.00104	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—GRB2—hematologic cancer	0.000171	0.00104	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CSF2—hematologic cancer	0.000169	0.00102	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CNR2—hematologic cancer	0.000165	0.001	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PDE4B—hematologic cancer	0.000165	0.001	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—hematologic cancer	0.000164	0.000999	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—FGF19—hematologic cancer	0.000164	0.000995	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PRKCG—hematologic cancer	0.000163	0.000989	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—JAK1—hematologic cancer	0.000163	0.000989	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—RAC2—hematologic cancer	0.000163	0.000987	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—DKK1—hematologic cancer	0.000161	0.000979	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—STAT5B—hematologic cancer	0.00016	0.000971	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—ADCY7—hematologic cancer	0.000155	0.000943	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CSF2—hematologic cancer	0.000153	0.00093	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—IL2RA—hematologic cancer	0.000152	0.000924	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—XIAP—hematologic cancer	0.000151	0.000917	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—JAK1—hematologic cancer	0.000148	0.000898	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PRKCG—hematologic cancer	0.000148	0.000898	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SH2B3—hematologic cancer	0.000147	0.000894	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SMARCA4—hematologic cancer	0.000147	0.000894	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—GZMB—hematologic cancer	0.000146	0.000889	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CTNNA1—hematologic cancer	0.000143	0.000868	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—EIF4EBP1—hematologic cancer	0.000142	0.000863	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CCL3—hematologic cancer	0.000142	0.000863	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HSPB1—hematologic cancer	0.000142	0.000863	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PTHLH—hematologic cancer	0.00014	0.000853	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SDC1—hematologic cancer	0.00014	0.000853	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—IL2RA—hematologic cancer	0.000138	0.000839	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PTGER4—hematologic cancer	0.000137	0.00083	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—LCK—hematologic cancer	0.000136	0.000826	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—H3F3A—hematologic cancer	0.000133	0.00081	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PRKCZ—hematologic cancer	0.00013	0.000787	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CG—hematologic cancer	0.000127	0.000769	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PARP1—hematologic cancer	0.000125	0.00076	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—FBXW7—hematologic cancer	0.000123	0.000748	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HDAC2—hematologic cancer	0.000121	0.000733	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CXCR4—hematologic cancer	0.000121	0.000733	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CBL—hematologic cancer	0.000118	0.000715	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IL3—hematologic cancer	0.000116	0.000707	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PIK3CG—hematologic cancer	0.000115	0.000699	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PTPN1—hematologic cancer	0.000115	0.000695	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PTPN11—hematologic cancer	0.000113	0.000686	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—RASGRP1—hematologic cancer	0.000113	0.000684	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SYK—hematologic cancer	0.000112	0.000682	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HSP90AA1—hematologic cancer	0.000112	0.000682	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CD—hematologic cancer	0.000111	0.000676	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CREB1—hematologic cancer	0.00011	0.000665	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—STAT1—hematologic cancer	0.000108	0.000657	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CCL2—hematologic cancer	0.000107	0.000651	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—IL6R—hematologic cancer	0.000107	0.000649	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PIK3R1—hematologic cancer	0.000105	0.000639	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—JAK2—hematologic cancer	0.000102	0.000621	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—MAP2K1—hematologic cancer	0.000102	0.000618	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—GRB2—hematologic cancer	0.000101	0.000615	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PIK3CD—hematologic cancer	0.000101	0.000614	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PDGFA—hematologic cancer	0.000101	0.000614	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—KITLG—hematologic cancer	9.96e-05	0.000605	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—STAT5A—hematologic cancer	9.74e-05	0.000591	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CB—hematologic cancer	9.71e-05	0.00059	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CDKN2B—hematologic cancer	9.65e-05	0.000586	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PIK3R1—hematologic cancer	9.55e-05	0.00058	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CD86—hematologic cancer	9.33e-05	0.000567	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—JAK2—hematologic cancer	9.28e-05	0.000564	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HES1—hematologic cancer	9.21e-05	0.000559	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—NCOR1—hematologic cancer	9.15e-05	0.000556	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CSF2—hematologic cancer	9.05e-05	0.00055	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—FGF1—hematologic cancer	9.05e-05	0.00055	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—FOXO1—hematologic cancer	8.92e-05	0.000542	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—IL2—hematologic cancer	8.92e-05	0.000541	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PDGFRB—hematologic cancer	8.9e-05	0.000541	CbGpPWpGaD
Travoprost—Hypotension—Dexamethasone—hematologic cancer	8.83e-05	0.000136	CcSEcCtD
Travoprost—Nausea—Carmustine—hematologic cancer	8.82e-05	0.000136	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—PIK3CB—hematologic cancer	8.82e-05	0.000535	CbGpPWpGaD
Travoprost—Angiopathy—Methotrexate—hematologic cancer	8.78e-05	0.000135	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PDGFRA—hematologic cancer	8.77e-05	0.000532	CbGpPWpGaD
Travoprost—Sinusitis—Doxorubicin—hematologic cancer	8.76e-05	0.000135	CcSEcCtD
Travoprost—Immune system disorder—Methotrexate—hematologic cancer	8.74e-05	0.000135	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—JAK1—hematologic cancer	8.74e-05	0.00053	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PRKCG—hematologic cancer	8.74e-05	0.00053	CbGpPWpGaD
Travoprost—Nausea—Alitretinoin—hematologic cancer	8.74e-05	0.000135	CcSEcCtD
Travoprost—Visual impairment—Epirubicin—hematologic cancer	8.73e-05	0.000135	CcSEcCtD
Travoprost—Mediastinal disorder—Methotrexate—hematologic cancer	8.72e-05	0.000134	CcSEcCtD
Travoprost—Hypertension—Prednisone—hematologic cancer	8.7e-05	0.000134	CcSEcCtD
Travoprost—Rash—Mitoxantrone—hematologic cancer	8.7e-05	0.000134	CcSEcCtD
Travoprost—Rash—Irinotecan—hematologic cancer	8.7e-05	0.000134	CcSEcCtD
Travoprost—Dermatitis—Mitoxantrone—hematologic cancer	8.69e-05	0.000134	CcSEcCtD
Travoprost—Dermatitis—Irinotecan—hematologic cancer	8.69e-05	0.000134	CcSEcCtD
Travoprost—Headache—Mitoxantrone—hematologic cancer	8.65e-05	0.000133	CcSEcCtD
Travoprost—Headache—Irinotecan—hematologic cancer	8.65e-05	0.000133	CcSEcCtD
Travoprost—Nausea—Ifosfamide—hematologic cancer	8.63e-05	0.000133	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Betamethasone—hematologic cancer	8.61e-05	0.000133	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	8.61e-05	0.000133	CcSEcCtD
Travoprost—Arthralgia—Prednisone—hematologic cancer	8.58e-05	0.000132	CcSEcCtD
Travoprost—Myalgia—Prednisone—hematologic cancer	8.58e-05	0.000132	CcSEcCtD
Travoprost—Feeling abnormal—Triamcinolone—hematologic cancer	8.58e-05	0.000132	CcSEcCtD
Travoprost—Diarrhoea—Cisplatin—hematologic cancer	8.57e-05	0.000132	CcSEcCtD
Travoprost—Anxiety—Prednisone—hematologic cancer	8.55e-05	0.000132	CcSEcCtD
Travoprost—Bradycardia—Doxorubicin—hematologic cancer	8.53e-05	0.000131	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	8.52e-05	0.000131	CcSEcCtD
Travoprost—Discomfort—Prednisone—hematologic cancer	8.48e-05	0.000131	CcSEcCtD
Travoprost—Mental disorder—Methotrexate—hematologic cancer	8.48e-05	0.000131	CcSEcCtD
Travoprost—Rash—Gemcitabine—hematologic cancer	8.48e-05	0.000131	CcSEcCtD
Travoprost—Dermatitis—Gemcitabine—hematologic cancer	8.47e-05	0.000131	CcSEcCtD
Travoprost—Eye disorder—Epirubicin—hematologic cancer	8.46e-05	0.00013	CcSEcCtD
Travoprost—Hypersensitivity—Etoposide—hematologic cancer	8.46e-05	0.00013	CcSEcCtD
Travoprost—Tinnitus—Epirubicin—hematologic cancer	8.44e-05	0.00013	CcSEcCtD
Travoprost—Erythema—Methotrexate—hematologic cancer	8.43e-05	0.00013	CcSEcCtD
Travoprost—Headache—Gemcitabine—hematologic cancer	8.42e-05	0.00013	CcSEcCtD
Travoprost—Nausea—Vincristine—hematologic cancer	8.42e-05	0.00013	CcSEcCtD
Travoprost—Cardiac disorder—Epirubicin—hematologic cancer	8.41e-05	0.00013	CcSEcCtD
Travoprost—Rhinitis—Doxorubicin—hematologic cancer	8.4e-05	0.000129	CcSEcCtD
Travoprost—Hypersensitivity—Prednisolone—hematologic cancer	8.34e-05	0.000129	CcSEcCtD
Travoprost—Pharyngitis—Doxorubicin—hematologic cancer	8.32e-05	0.000128	CcSEcCtD
Travoprost—Dyspepsia—Betamethasone—hematologic cancer	8.32e-05	0.000128	CcSEcCtD
Travoprost—Dyspepsia—Dexamethasone—hematologic cancer	8.32e-05	0.000128	CcSEcCtD
Travoprost—Urinary tract disorder—Doxorubicin—hematologic cancer	8.28e-05	0.000128	CcSEcCtD
Travoprost—Dysgeusia—Methotrexate—hematologic cancer	8.25e-05	0.000127	CcSEcCtD
Travoprost—Asthenia—Etoposide—hematologic cancer	8.24e-05	0.000127	CcSEcCtD
Travoprost—Connective tissue disorder—Doxorubicin—hematologic cancer	8.24e-05	0.000127	CcSEcCtD
Travoprost—Oedema—Prednisone—hematologic cancer	8.23e-05	0.000127	CcSEcCtD
Travoprost—Angiopathy—Epirubicin—hematologic cancer	8.22e-05	0.000127	CcSEcCtD
Travoprost—Urethral disorder—Doxorubicin—hematologic cancer	8.21e-05	0.000127	CcSEcCtD
Travoprost—Nausea—Irinotecan—hematologic cancer	8.2e-05	0.000126	CcSEcCtD
Travoprost—Nausea—Mitoxantrone—hematologic cancer	8.2e-05	0.000126	CcSEcCtD
Travoprost—Immune system disorder—Epirubicin—hematologic cancer	8.18e-05	0.000126	CcSEcCtD
Travoprost—Infection—Prednisone—hematologic cancer	8.17e-05	0.000126	CcSEcCtD
Travoprost—Mediastinal disorder—Epirubicin—hematologic cancer	8.16e-05	0.000126	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—IL2RA—hematologic cancer	8.16e-05	0.000495	CbGpPWpGaD
Travoprost—Gastrointestinal disorder—Betamethasone—hematologic cancer	8.16e-05	0.000126	CcSEcCtD
Travoprost—Gastrointestinal disorder—Dexamethasone—hematologic cancer	8.16e-05	0.000126	CcSEcCtD
Travoprost—Back pain—Methotrexate—hematologic cancer	8.15e-05	0.000126	CcSEcCtD
Travoprost—Fatigue—Dexamethasone—hematologic cancer	8.15e-05	0.000126	CcSEcCtD
Travoprost—Fatigue—Betamethasone—hematologic cancer	8.15e-05	0.000126	CcSEcCtD
Travoprost—Pruritus—Etoposide—hematologic cancer	8.12e-05	0.000125	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—IL2—hematologic cancer	8.1e-05	0.000492	CbGpPWpGaD
Travoprost—Pain—Betamethasone—hematologic cancer	8.08e-05	0.000125	CcSEcCtD
Travoprost—Pain—Dexamethasone—hematologic cancer	8.08e-05	0.000125	CcSEcCtD
Travoprost—Visual impairment—Doxorubicin—hematologic cancer	8.08e-05	0.000124	CcSEcCtD
Travoprost—Nervous system disorder—Prednisone—hematologic cancer	8.07e-05	0.000124	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—TERT—hematologic cancer	8.07e-05	0.00049	CbGpPWpGaD
Travoprost—Tachycardia—Prednisone—hematologic cancer	8.03e-05	0.000124	CcSEcCtD
Travoprost—Skin disorder—Prednisone—hematologic cancer	7.99e-05	0.000123	CcSEcCtD
Travoprost—Nausea—Gemcitabine—hematologic cancer	7.99e-05	0.000123	CcSEcCtD
Travoprost—Vision blurred—Methotrexate—hematologic cancer	7.94e-05	0.000122	CcSEcCtD
Travoprost—Mental disorder—Epirubicin—hematologic cancer	7.93e-05	0.000122	CcSEcCtD
Travoprost—Rash—Cisplatin—hematologic cancer	7.9e-05	0.000122	CcSEcCtD
Travoprost—Dermatitis—Cisplatin—hematologic cancer	7.89e-05	0.000122	CcSEcCtD
Travoprost—Erythema—Epirubicin—hematologic cancer	7.88e-05	0.000122	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PDGFB—hematologic cancer	7.87e-05	0.000478	CbGpPWpGaD
Travoprost—Diarrhoea—Etoposide—hematologic cancer	7.85e-05	0.000121	CcSEcCtD
Travoprost—Eye disorder—Doxorubicin—hematologic cancer	7.83e-05	0.000121	CcSEcCtD
Travoprost—Ill-defined disorder—Methotrexate—hematologic cancer	7.82e-05	0.00012	CcSEcCtD
Travoprost—Tinnitus—Doxorubicin—hematologic cancer	7.81e-05	0.00012	CcSEcCtD
Travoprost—Feeling abnormal—Betamethasone—hematologic cancer	7.79e-05	0.00012	CcSEcCtD
Travoprost—Feeling abnormal—Dexamethasone—hematologic cancer	7.79e-05	0.00012	CcSEcCtD
Travoprost—Cardiac disorder—Doxorubicin—hematologic cancer	7.78e-05	0.00012	CcSEcCtD
Travoprost—Gastrointestinal pain—Dexamethasone—hematologic cancer	7.73e-05	0.000119	CcSEcCtD
Travoprost—Gastrointestinal pain—Betamethasone—hematologic cancer	7.73e-05	0.000119	CcSEcCtD
Travoprost—Dysgeusia—Epirubicin—hematologic cancer	7.72e-05	0.000119	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—TSC2—hematologic cancer	7.7e-05	0.000467	CbGpPWpGaD
Travoprost—Hypersensitivity—Triamcinolone—hematologic cancer	7.67e-05	0.000118	CcSEcCtD
Travoprost—Back pain—Epirubicin—hematologic cancer	7.63e-05	0.000118	CcSEcCtD
Travoprost—Angiopathy—Doxorubicin—hematologic cancer	7.6e-05	0.000117	CcSEcCtD
Travoprost—Malaise—Methotrexate—hematologic cancer	7.6e-05	0.000117	CcSEcCtD
Travoprost—Dizziness—Etoposide—hematologic cancer	7.59e-05	0.000117	CcSEcCtD
Travoprost—Immune system disorder—Doxorubicin—hematologic cancer	7.57e-05	0.000117	CcSEcCtD
Travoprost—Vertigo—Methotrexate—hematologic cancer	7.57e-05	0.000117	CcSEcCtD
Travoprost—Mediastinal disorder—Doxorubicin—hematologic cancer	7.55e-05	0.000116	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Prednisone—hematologic cancer	7.5e-05	0.000116	CcSEcCtD
Travoprost—Dizziness—Prednisolone—hematologic cancer	7.49e-05	0.000115	CcSEcCtD
Travoprost—Asthenia—Triamcinolone—hematologic cancer	7.47e-05	0.000115	CcSEcCtD
Travoprost—Abdominal pain—Dexamethasone—hematologic cancer	7.47e-05	0.000115	CcSEcCtD
Travoprost—Abdominal pain—Betamethasone—hematologic cancer	7.47e-05	0.000115	CcSEcCtD
Travoprost—Nausea—Cisplatin—hematologic cancer	7.44e-05	0.000115	CcSEcCtD
Travoprost—Vision blurred—Epirubicin—hematologic cancer	7.43e-05	0.000115	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—FGFR3—hematologic cancer	7.4e-05	0.00045	CbGpPWpGaD
Travoprost—Pruritus—Triamcinolone—hematologic cancer	7.37e-05	0.000114	CcSEcCtD
Travoprost—Cough—Methotrexate—hematologic cancer	7.35e-05	0.000113	CcSEcCtD
Travoprost—Mental disorder—Doxorubicin—hematologic cancer	7.34e-05	0.000113	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—MAPK14—hematologic cancer	7.33e-05	0.000445	CbGpPWpGaD
Travoprost—Ill-defined disorder—Epirubicin—hematologic cancer	7.32e-05	0.000113	CcSEcCtD
Travoprost—Erythema—Doxorubicin—hematologic cancer	7.3e-05	0.000112	CcSEcCtD
Travoprost—Dyspepsia—Prednisone—hematologic cancer	7.24e-05	0.000112	CcSEcCtD
Travoprost—Rash—Etoposide—hematologic cancer	7.24e-05	0.000112	CcSEcCtD
Travoprost—Dermatitis—Etoposide—hematologic cancer	7.23e-05	0.000111	CcSEcCtD
Travoprost—Headache—Etoposide—hematologic cancer	7.19e-05	0.000111	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—ESR1—hematologic cancer	7.19e-05	0.000437	CbGpPWpGaD
Travoprost—Arthralgia—Methotrexate—hematologic cancer	7.17e-05	0.000111	CcSEcCtD
Travoprost—Chest pain—Methotrexate—hematologic cancer	7.17e-05	0.000111	CcSEcCtD
Travoprost—Myalgia—Methotrexate—hematologic cancer	7.17e-05	0.000111	CcSEcCtD
Travoprost—Dysgeusia—Doxorubicin—hematologic cancer	7.14e-05	0.00011	CcSEcCtD
Travoprost—Rash—Prednisolone—hematologic cancer	7.14e-05	0.00011	CcSEcCtD
Travoprost—Dermatitis—Prednisolone—hematologic cancer	7.13e-05	0.00011	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	7.12e-05	0.00011	CcSEcCtD
Travoprost—Malaise—Epirubicin—hematologic cancer	7.11e-05	0.00011	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—FN1—hematologic cancer	7.1e-05	0.000431	CbGpPWpGaD
Travoprost—Fatigue—Prednisone—hematologic cancer	7.09e-05	0.000109	CcSEcCtD
Travoprost—Headache—Prednisolone—hematologic cancer	7.09e-05	0.000109	CcSEcCtD
Travoprost—Discomfort—Methotrexate—hematologic cancer	7.09e-05	0.000109	CcSEcCtD
Travoprost—Vertigo—Epirubicin—hematologic cancer	7.08e-05	0.000109	CcSEcCtD
Travoprost—Back pain—Doxorubicin—hematologic cancer	7.06e-05	0.000109	CcSEcCtD
Travoprost—Constipation—Prednisone—hematologic cancer	7.04e-05	0.000108	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—BAD—hematologic cancer	7.02e-05	0.000426	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—NFKBIA—hematologic cancer	7.02e-05	0.000426	CbGpPWpGaD
Travoprost—Palpitations—Epirubicin—hematologic cancer	6.97e-05	0.000107	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—NOTCH1—hematologic cancer	6.95e-05	0.000422	CbGpPWpGaD
Travoprost—Dizziness—Triamcinolone—hematologic cancer	6.89e-05	0.000106	CcSEcCtD
Travoprost—Cough—Epirubicin—hematologic cancer	6.88e-05	0.000106	CcSEcCtD
Travoprost—Vision blurred—Doxorubicin—hematologic cancer	6.88e-05	0.000106	CcSEcCtD
Travoprost—Infection—Methotrexate—hematologic cancer	6.83e-05	0.000105	CcSEcCtD
Travoprost—Nausea—Etoposide—hematologic cancer	6.82e-05	0.000105	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—CD80—hematologic cancer	6.81e-05	0.000413	CbGpPWpGaD
Travoprost—Hypertension—Epirubicin—hematologic cancer	6.81e-05	0.000105	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PIK3CG—hematologic cancer	6.8e-05	0.000413	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—KIT—hematologic cancer	6.8e-05	0.000413	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—NRAS—hematologic cancer	6.8e-05	0.000413	CbGpPWpGaD
Travoprost—Feeling abnormal—Prednisone—hematologic cancer	6.78e-05	0.000104	CcSEcCtD
Travoprost—Asthenia—Betamethasone—hematologic cancer	6.78e-05	0.000104	CcSEcCtD
Travoprost—Asthenia—Dexamethasone—hematologic cancer	6.78e-05	0.000104	CcSEcCtD
Travoprost—Ill-defined disorder—Doxorubicin—hematologic cancer	6.77e-05	0.000104	CcSEcCtD
Travoprost—Nervous system disorder—Methotrexate—hematologic cancer	6.74e-05	0.000104	CcSEcCtD
Travoprost—Gastrointestinal pain—Prednisone—hematologic cancer	6.73e-05	0.000104	CcSEcCtD
Travoprost—Nausea—Prednisolone—hematologic cancer	6.73e-05	0.000104	CcSEcCtD
Travoprost—Chest pain—Epirubicin—hematologic cancer	6.71e-05	0.000103	CcSEcCtD
Travoprost—Myalgia—Epirubicin—hematologic cancer	6.71e-05	0.000103	CcSEcCtD
Travoprost—Arthralgia—Epirubicin—hematologic cancer	6.71e-05	0.000103	CcSEcCtD
Travoprost—Anxiety—Epirubicin—hematologic cancer	6.69e-05	0.000103	CcSEcCtD
Travoprost—Pruritus—Dexamethasone—hematologic cancer	6.68e-05	0.000103	CcSEcCtD
Travoprost—Pruritus—Betamethasone—hematologic cancer	6.68e-05	0.000103	CcSEcCtD
Travoprost—Skin disorder—Methotrexate—hematologic cancer	6.68e-05	0.000103	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PTPN11—hematologic cancer	6.68e-05	0.000405	CbGpPWpGaD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	6.67e-05	0.000103	CcSEcCtD
Travoprost—Discomfort—Epirubicin—hematologic cancer	6.63e-05	0.000102	CcSEcCtD
Travoprost—Malaise—Doxorubicin—hematologic cancer	6.58e-05	0.000101	CcSEcCtD
Travoprost—Rash—Triamcinolone—hematologic cancer	6.57e-05	0.000101	CcSEcCtD
Travoprost—Dry mouth—Epirubicin—hematologic cancer	6.56e-05	0.000101	CcSEcCtD
Travoprost—Dermatitis—Triamcinolone—hematologic cancer	6.56e-05	0.000101	CcSEcCtD
Travoprost—Vertigo—Doxorubicin—hematologic cancer	6.55e-05	0.000101	CcSEcCtD
Travoprost—Headache—Triamcinolone—hematologic cancer	6.52e-05	0.000101	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—MAPK3—hematologic cancer	6.51e-05	0.000395	CbGpPWpGaD
Travoprost—Abdominal pain—Prednisone—hematologic cancer	6.5e-05	0.0001	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—CREB1—hematologic cancer	6.47e-05	0.000393	CbGpPWpGaD
Travoprost—Diarrhoea—Betamethasone—hematologic cancer	6.46e-05	9.96e-05	CcSEcCtD
Travoprost—Diarrhoea—Dexamethasone—hematologic cancer	6.46e-05	9.96e-05	CcSEcCtD
Travoprost—Palpitations—Doxorubicin—hematologic cancer	6.45e-05	9.94e-05	CcSEcCtD
Travoprost—Oedema—Epirubicin—hematologic cancer	6.43e-05	9.92e-05	CcSEcCtD
Travoprost—Hypotension—Methotrexate—hematologic cancer	6.43e-05	9.9e-05	CcSEcCtD
Travoprost—Infection—Epirubicin—hematologic cancer	6.39e-05	9.85e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—BRAF—hematologic cancer	6.39e-05	0.000388	CbGpPWpGaD
Travoprost—Cough—Doxorubicin—hematologic cancer	6.37e-05	9.81e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—CCL2—hematologic cancer	6.33e-05	0.000384	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IL6R—hematologic cancer	6.31e-05	0.000383	CbGpPWpGaD
Travoprost—Nervous system disorder—Epirubicin—hematologic cancer	6.31e-05	9.73e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—CREBBP—hematologic cancer	6.3e-05	0.000383	CbGpPWpGaD
Travoprost—Hypertension—Doxorubicin—hematologic cancer	6.3e-05	9.71e-05	CcSEcCtD
Travoprost—Tachycardia—Epirubicin—hematologic cancer	6.28e-05	9.68e-05	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Methotrexate—hematologic cancer	6.26e-05	9.65e-05	CcSEcCtD
Travoprost—Skin disorder—Epirubicin—hematologic cancer	6.25e-05	9.63e-05	CcSEcCtD
Travoprost—Dizziness—Dexamethasone—hematologic cancer	6.25e-05	9.63e-05	CcSEcCtD
Travoprost—Dizziness—Betamethasone—hematologic cancer	6.25e-05	9.63e-05	CcSEcCtD
Travoprost—Arthralgia—Doxorubicin—hematologic cancer	6.21e-05	9.57e-05	CcSEcCtD
Travoprost—Chest pain—Doxorubicin—hematologic cancer	6.21e-05	9.57e-05	CcSEcCtD
Travoprost—Myalgia—Doxorubicin—hematologic cancer	6.21e-05	9.57e-05	CcSEcCtD
Travoprost—Anxiety—Doxorubicin—hematologic cancer	6.19e-05	9.54e-05	CcSEcCtD
Travoprost—Nausea—Triamcinolone—hematologic cancer	6.18e-05	9.53e-05	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	6.17e-05	9.51e-05	CcSEcCtD
Travoprost—Discomfort—Doxorubicin—hematologic cancer	6.14e-05	9.46e-05	CcSEcCtD
Travoprost—Dyspnoea—Methotrexate—hematologic cancer	6.13e-05	9.45e-05	CcSEcCtD
Travoprost—Dry mouth—Doxorubicin—hematologic cancer	6.07e-05	9.36e-05	CcSEcCtD
Travoprost—Hypersensitivity—Prednisone—hematologic cancer	6.06e-05	9.34e-05	CcSEcCtD
Travoprost—Dyspepsia—Methotrexate—hematologic cancer	6.05e-05	9.33e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—MAP2K1—hematologic cancer	6.01e-05	0.000365	CbGpPWpGaD
Travoprost—Hypotension—Epirubicin—hematologic cancer	6.01e-05	9.27e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PIK3CD—hematologic cancer	5.98e-05	0.000363	CbGpPWpGaD
Travoprost—Rash—Dexamethasone—hematologic cancer	5.96e-05	9.18e-05	CcSEcCtD
Travoprost—Rash—Betamethasone—hematologic cancer	5.96e-05	9.18e-05	CcSEcCtD
Travoprost—Oedema—Doxorubicin—hematologic cancer	5.95e-05	9.18e-05	CcSEcCtD
Travoprost—Dermatitis—Betamethasone—hematologic cancer	5.95e-05	9.17e-05	CcSEcCtD
Travoprost—Dermatitis—Dexamethasone—hematologic cancer	5.95e-05	9.17e-05	CcSEcCtD
Travoprost—Gastrointestinal disorder—Methotrexate—hematologic cancer	5.94e-05	9.15e-05	CcSEcCtD
Travoprost—Fatigue—Methotrexate—hematologic cancer	5.93e-05	9.14e-05	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CA—hematologic cancer	5.92e-05	0.000359	CbGpPWpGaD
Travoprost—Headache—Betamethasone—hematologic cancer	5.92e-05	9.12e-05	CcSEcCtD
Travoprost—Headache—Dexamethasone—hematologic cancer	5.92e-05	9.12e-05	CcSEcCtD
Travoprost—Infection—Doxorubicin—hematologic cancer	5.92e-05	9.12e-05	CcSEcCtD
Travoprost—Asthenia—Prednisone—hematologic cancer	5.9e-05	9.1e-05	CcSEcCtD
Travoprost—Pain—Methotrexate—hematologic cancer	5.88e-05	9.06e-05	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Epirubicin—hematologic cancer	5.86e-05	9.04e-05	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—KRAS—hematologic cancer	5.85e-05	0.000355	CbGpPWpGaD
Travoprost—Nervous system disorder—Doxorubicin—hematologic cancer	5.84e-05	9e-05	CcSEcCtD
Travoprost—Pruritus—Prednisone—hematologic cancer	5.82e-05	8.97e-05	CcSEcCtD
Travoprost—Tachycardia—Doxorubicin—hematologic cancer	5.81e-05	8.96e-05	CcSEcCtD
Travoprost—Skin disorder—Doxorubicin—hematologic cancer	5.78e-05	8.91e-05	CcSEcCtD
Travoprost—Dyspnoea—Epirubicin—hematologic cancer	5.74e-05	8.84e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—FGF2—hematologic cancer	5.72e-05	0.000347	CbGpPWpGaD
Travoprost—Feeling abnormal—Methotrexate—hematologic cancer	5.67e-05	8.73e-05	CcSEcCtD
Travoprost—Dyspepsia—Epirubicin—hematologic cancer	5.66e-05	8.73e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PIK3R1—hematologic cancer	5.64e-05	0.000343	CbGpPWpGaD
Travoprost—Diarrhoea—Prednisone—hematologic cancer	5.63e-05	8.68e-05	CcSEcCtD
Travoprost—Gastrointestinal pain—Methotrexate—hematologic cancer	5.62e-05	8.67e-05	CcSEcCtD
Travoprost—Nausea—Betamethasone—hematologic cancer	5.61e-05	8.65e-05	CcSEcCtD
Travoprost—Nausea—Dexamethasone—hematologic cancer	5.61e-05	8.65e-05	CcSEcCtD
Travoprost—Hypotension—Doxorubicin—hematologic cancer	5.56e-05	8.57e-05	CcSEcCtD
Travoprost—Gastrointestinal disorder—Epirubicin—hematologic cancer	5.56e-05	8.56e-05	CcSEcCtD
Travoprost—Fatigue—Epirubicin—hematologic cancer	5.55e-05	8.55e-05	CcSEcCtD
Travoprost—Pain—Epirubicin—hematologic cancer	5.5e-05	8.48e-05	CcSEcCtD
Travoprost—Constipation—Epirubicin—hematologic cancer	5.5e-05	8.48e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—JAK2—hematologic cancer	5.48e-05	0.000333	CbGpPWpGaD
Travoprost—Dizziness—Prednisone—hematologic cancer	5.44e-05	8.39e-05	CcSEcCtD
Travoprost—Abdominal pain—Methotrexate—hematologic cancer	5.44e-05	8.38e-05	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	5.42e-05	8.36e-05	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—PIK3CA—hematologic cancer	5.37e-05	0.000326	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MDM2—hematologic cancer	5.35e-05	0.000325	CbGpPWpGaD
Travoprost—Dyspnoea—Doxorubicin—hematologic cancer	5.31e-05	8.18e-05	CcSEcCtD
Travoprost—Feeling abnormal—Epirubicin—hematologic cancer	5.3e-05	8.17e-05	CcSEcCtD
Travoprost—Gastrointestinal pain—Epirubicin—hematologic cancer	5.26e-05	8.11e-05	CcSEcCtD
Travoprost—Dyspepsia—Doxorubicin—hematologic cancer	5.24e-05	8.08e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—MTOR—hematologic cancer	5.21e-05	0.000316	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PIK3CB—hematologic cancer	5.21e-05	0.000316	CbGpPWpGaD
Travoprost—Rash—Prednisone—hematologic cancer	5.19e-05	8e-05	CcSEcCtD
Travoprost—Dermatitis—Prednisone—hematologic cancer	5.18e-05	7.99e-05	CcSEcCtD
Travoprost—Headache—Prednisone—hematologic cancer	5.15e-05	7.94e-05	CcSEcCtD
Travoprost—Gastrointestinal disorder—Doxorubicin—hematologic cancer	5.14e-05	7.92e-05	CcSEcCtD
Travoprost—Fatigue—Doxorubicin—hematologic cancer	5.13e-05	7.91e-05	CcSEcCtD
Travoprost—Pain—Doxorubicin—hematologic cancer	5.09e-05	7.85e-05	CcSEcCtD
Travoprost—Constipation—Doxorubicin—hematologic cancer	5.09e-05	7.85e-05	CcSEcCtD
Travoprost—Abdominal pain—Epirubicin—hematologic cancer	5.09e-05	7.84e-05	CcSEcCtD
Travoprost—Hypersensitivity—Methotrexate—hematologic cancer	5.07e-05	7.81e-05	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—HRAS—hematologic cancer	4.97e-05	0.000302	CbGpPWpGaD
Travoprost—Asthenia—Methotrexate—hematologic cancer	4.93e-05	7.6e-05	CcSEcCtD
Travoprost—Feeling abnormal—Doxorubicin—hematologic cancer	4.91e-05	7.56e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—CDKN1B—hematologic cancer	4.89e-05	0.000297	CbGpPWpGaD
Travoprost—Nausea—Prednisone—hematologic cancer	4.89e-05	7.53e-05	CcSEcCtD
Travoprost—Gastrointestinal pain—Doxorubicin—hematologic cancer	4.87e-05	7.5e-05	CcSEcCtD
Travoprost—Pruritus—Methotrexate—hematologic cancer	4.86e-05	7.5e-05	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—AKT1—hematologic cancer	4.83e-05	0.000294	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CASP3—hematologic cancer	4.79e-05	0.000291	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IL2—hematologic cancer	4.78e-05	0.00029	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—IL6—hematologic cancer	4.76e-05	0.000289	CbGpPWpGaD
Travoprost—Hypersensitivity—Epirubicin—hematologic cancer	4.74e-05	7.31e-05	CcSEcCtD
Travoprost—Abdominal pain—Doxorubicin—hematologic cancer	4.71e-05	7.25e-05	CcSEcCtD
Travoprost—Diarrhoea—Methotrexate—hematologic cancer	4.7e-05	7.25e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—CCND1—hematologic cancer	4.66e-05	0.000283	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—JUN—hematologic cancer	4.65e-05	0.000283	CbGpPWpGaD
Travoprost—Asthenia—Epirubicin—hematologic cancer	4.62e-05	7.12e-05	CcSEcCtD
Travoprost—Pruritus—Epirubicin—hematologic cancer	4.55e-05	7.02e-05	CcSEcCtD
Travoprost—Dizziness—Methotrexate—hematologic cancer	4.55e-05	7.01e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—CDKN1A—hematologic cancer	4.51e-05	0.000274	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PTEN—hematologic cancer	4.5e-05	0.000273	CbGpPWpGaD
Travoprost—Diarrhoea—Epirubicin—hematologic cancer	4.4e-05	6.79e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—MAPK8—hematologic cancer	4.4e-05	0.000267	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—AKT1—hematologic cancer	4.39e-05	0.000267	CbGpPWpGaD
Travoprost—Hypersensitivity—Doxorubicin—hematologic cancer	4.39e-05	6.76e-05	CcSEcCtD
Travoprost—Rash—Methotrexate—hematologic cancer	4.34e-05	6.68e-05	CcSEcCtD
Travoprost—Dermatitis—Methotrexate—hematologic cancer	4.33e-05	6.68e-05	CcSEcCtD
Travoprost—Headache—Methotrexate—hematologic cancer	4.31e-05	6.64e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—EP300—hematologic cancer	4.29e-05	0.000261	CbGpPWpGaD
Travoprost—Asthenia—Doxorubicin—hematologic cancer	4.27e-05	6.58e-05	CcSEcCtD
Travoprost—Dizziness—Epirubicin—hematologic cancer	4.26e-05	6.56e-05	CcSEcCtD
Travoprost—Pruritus—Doxorubicin—hematologic cancer	4.21e-05	6.49e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—SRC—hematologic cancer	4.17e-05	0.000253	CbGpPWpGaD
Travoprost—Nausea—Methotrexate—hematologic cancer	4.08e-05	6.29e-05	CcSEcCtD
Travoprost—Diarrhoea—Doxorubicin—hematologic cancer	4.07e-05	6.28e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—VEGFA—hematologic cancer	4.06e-05	0.000247	CbGpPWpGaD
Travoprost—Rash—Epirubicin—hematologic cancer	4.06e-05	6.25e-05	CcSEcCtD
Travoprost—Dermatitis—Epirubicin—hematologic cancer	4.05e-05	6.25e-05	CcSEcCtD
Travoprost—Headache—Epirubicin—hematologic cancer	4.03e-05	6.21e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—STAT3—hematologic cancer	4.02e-05	0.000244	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—NRAS—hematologic cancer	4.02e-05	0.000244	CbGpPWpGaD
Travoprost—Dizziness—Doxorubicin—hematologic cancer	3.94e-05	6.07e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—MAPK3—hematologic cancer	3.85e-05	0.000233	CbGpPWpGaD
Travoprost—Nausea—Epirubicin—hematologic cancer	3.82e-05	5.89e-05	CcSEcCtD
Travoprost—Rash—Doxorubicin—hematologic cancer	3.75e-05	5.79e-05	CcSEcCtD
Travoprost—Dermatitis—Doxorubicin—hematologic cancer	3.75e-05	5.78e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—MYC—hematologic cancer	3.74e-05	0.000227	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TGFB1—hematologic cancer	3.73e-05	0.000227	CbGpPWpGaD
Travoprost—Headache—Doxorubicin—hematologic cancer	3.73e-05	5.75e-05	CcSEcCtD
Travoprost—Nausea—Doxorubicin—hematologic cancer	3.54e-05	5.45e-05	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—KRAS—hematologic cancer	3.46e-05	0.00021	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PIK3CA—hematologic cancer	3.17e-05	0.000193	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TP53—hematologic cancer	3.07e-05	0.000187	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HRAS—hematologic cancer	2.94e-05	0.000178	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IL6—hematologic cancer	2.81e-05	0.000171	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—AKT1—hematologic cancer	2.59e-05	0.000157	CbGpPWpGaD
